Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer Files Xalkori for ROS1-Positive Lung Cancer in Japan
September 1, 2016
- Harvoni Outstrips Plavix to Top FY2015 Japan Sales Ranking: Jiho Tally
September 1, 2016
- Kyowa Kirin Completes Construction of API Manufacturing Facility for Biopharmaceuticals
September 1, 2016
- Lonsurf Now Available in UK with Health Coverage: Taiho
August 31, 2016
- Data Support Lixiana’s Efficacy in AF Patients Undergoing Cardioversion
August 31, 2016
- Mitsubishi Tanabe’s ALS Drug Gets PDUFA Date of June 16, 2017
August 31, 2016
- Sumitomo Dainippon to Shed Jobs for Leaner Japan Operations
August 31, 2016
- Lilly to Withdraw Taltz from Wholesaler Inventory; Distributor Execs Irked by MHLW’s Price Handling
August 31, 2016
- Santen, Kerui Set Up Ophthalmic JV in China
August 31, 2016
- Oropharyngeal Candidiasis Drug Hits Primary Endpoint in PIII: Sosei
August 30, 2016
- Seikagaku, Ferring Finalize Licensing Deal for Lumbar Disc Herniation Drug
August 30, 2016
- Nichi-Iko Completes Tender Offer for Sagent
August 30, 2016
- Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
August 30, 2016
- Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
August 30, 2016
- Mylan, Pfizer Recalling 2 Generic Products in Japan
August 29, 2016
- Vimpat Filed for Monotherapy Approval in Japan: Daiichi Sankyo, UCB
August 29, 2016
- Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
August 29, 2016
- CSL Behring Seeks Approval of Human Prothrombin Complex
August 26, 2016
- Actemra Filed for Weekly Dosage for Inadequately Controlled RA
August 26, 2016
- Mitsubishi Tanabe Transitions from “Open Innovation” to “Open Shared” System: President
August 26, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…